Spray before biopsy may curb bleeding and boost cancer diagnosis

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years old * Patients scheduled to undergo bronchoscopy, presenting a suspicious radiographic lesion and a lesion proximal tumor pace viewable in white light endoscopy and without pathologic diagnosis * Patient having read and understood the information letter and signed the consent form * Effective contraception in women of childbearing age Exclusion Criteria: * Patients with contraindication to the use of terlipressin: * septic shock , * Hypersensitivity to terlipressin or the excipients or by whom use the product is not recommended: * Recent history (\<3 months) of acute coronary syndrome (including myocardial infarction) or unbalanced coronary insufficiency, or disorders of the ventricular heart rate. * severe uncontrolled hypertension, * cerebrovascular insufficiency and ischemic stroke of recent origin (\<3 months). * severe arterial occlusive lower extremities, * severe chronic renal impairment (GFR \<20 ml / min). * Patients receiving uninterrupted antiplatelet therapy during 5 days before endoscopy (7 days for Clopidogrel Related), including low dose aspirin (≤ 75 mg / day). * Patients receiving anticoagulant therapy: * Unfractionated heparin within 12 hours before endoscopy. * low molecular weight heparin within 24 hours before endoscopy. * Patients with bleeding disorders defined by TP below 70% or TCA ratio patient / control greater than 1.3. * Patients with thrombocytopenia less than 100 g / L. * Subjects misunderstanding of spoken and written French * Person under guardianship or deprived of liberty by judicial or administrative decision (under Article L1121-6 and L1121-8 of Public Health Code * Pregnant or lactating women, premenopausal women without adequate contraception * Patient participating in other drug testing or participating in another drug test in the previous month